Table 3.
Asthma Control and Severity by Weight Status
| Healthy weight N=427 |
Overweight N=137 |
Obese N=251 |
Estimated effect across BMI Categories | p value* | |
|---|---|---|---|---|---|
| Asthma Symptoms, Adjusted OR (95% CI) | |||||
| Cough, wheeze or shortness of breath | ref | 0.81 (0.57,1.16) | 1.09 (0.83,1.45) | 1.04 (0.90,1.19) | 0.63 |
| Nocturnal | ref | 0.71 (0.43,1.17) | 1.27 (0.88,1.82) | 1.11 (0.92,1.34) | 0.28 |
| SABA use** | ref | 0.86 (0.59,1.24) | 1.02 (0.77,1.36) | 1.00 (0.87,1.16) | 0.98 |
| Uncontrolled asthma† | ref | 1.39 (0.90,2.14) | 0.92 (0.64,1.32) | 0.98 (0.82,1.17) | 0.80 |
| Acute Care Utilization, Adjusted OR (95% CI) | |||||
| Hospitalization | ref | 0.93 (0.55,1.56) | 1.31 (0.87,1.97) | 1.13 (0.92,1.39) | 0.23 |
| ED | ref | 1.09 (0.64,1.88) | 1.09 (0.70,1.70) | 1.05 (0.84,1.31) | 0.69 |
| Lung Function, β coefficient (95% CI) | |||||
| FEV1 | ref | −0.01 (−0.05,0.03) | −0.002 (−0.03,0.03) | −0.001 (−0.02,0.01) | 0.86 |
| FEV1/FVC % | ref | −0.01 (−0.03,0.004) | −0.01 (−0.02,0.005) | −0.01 (−0.01,0.002) | 0.15 |
| Log 10(FeNO) | ref | −0.11 (−0.32,0.10) | −0.17 (−0.35,0.001) | −0.09 (−0.17, −0.001) | 0.05 |
| Medications and Severity, β coefficient (95% CI) | |||||
| Treatment Step | ref | −0.05 (−0.38,0.28) | 0.15 (−0.13,0.42) | 0.68 (−0.07,0.20) | 0.33 |
| Asthma Severity Score | ref | −0.11 (−0.86,0.64) | 0.31 (−0.32,0.95) | 0.14 (−0.17,0.46) | 0.36 |
*
p value for trend across BMI groups
**
SABA - Short-acting beta agonist use
†
uncontrolled=ACT (Asthma Control Test) score ≤ 19
All analyses adjusted for race, ethnicity, age, gender, study site, controller medication, household income, and atopy groups.
Asthma characteristics were examined across atopic groups using binomial regression models for asthma symptoms, logistic regression models for healthcare utilization or linear regression models for lung function, medication treatment step and severity score.